ArticleScientific reports2020
Antibiofilm and antivirulence efficacy of myrtenol enhances the antibiotic susceptibility of Acinetobacter baumannii.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 83 citations in OpenAlex.
- Repurposing Fingolimod as an Antibacterial and Antibiofilm Agent against Carbapenem-ResistantACS omega · 2026Article
- Linalool exhibits potent antibacterial and anti-biofilm activity against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Synergistic attenuation of Aeromonas dhakensis virulence by dual deletion of PhoBR and KdpE two-component systems and its protective immunity in zebrafish.Applied microbiology and biotechnology · 2026Article
- Targeted sortase A inhibition by novel peptidomimetic antivirulents against staphylococcal infections.Microbiology spectrum · 2026Article
- In vitro interaction between Acinetobacter baumannii and human peripheral blood mononuclear cells.Archives of microbiology · 2026Article
- Experimental and molecular docking analyses of antibacterial activity in moroccan Rosmarinus officinalis essential oil.Scientific reports · 2026Article
- Attenuation of biofilm-encoding genes and virulence attributes in clinical isolates of Acinetobacter baumannii by essential oil derived from Myroxylon balsamum.Scientific reports · 2026Article
- Dual deletion of ugd and phoB Attenuates virulence and enhances vaccine potential in Aeromonas dhakensis.BMC veterinary research · 2026Article
- Fatty Acids as Prebiotics and Their Role in Antibiofilm Activity.Antibiotics (Basel, Switzerland) · 2026Review
- Deciphering the efficacy of staphyloxanthin-encapsulated niosomal nanovesicles to attenuate biofilm formation, quorum sensing, and meropenem persistence in Acinetobacter baumannii.BMC microbiology · 2025Article
- Incorporation of Edible Plant Extracts as Natural Food Preservatives: Green Extraction Methods, Antibacterial Mechanisms and Applications.Foods (Basel, Switzerland) · 2025Review
- Flavonoids interfere with biofilm formation by targeting diguanylate cyclases in multidrug resistant Vibrio cholerae.Scientific reports · 2025Article
- Sustainable Agronomical Practices Affect Essential Oil Composition ofPlants (Basel, Switzerland) · 2025Article
- Multiple Strategies for the Application of Medicinal Plant-Derived Bioactive Compounds in Controlling Microbial Biofilm and Virulence Properties.Antibiotics (Basel, Switzerland) · 2025Review
- Evaluation of Cinnamon Essential Oil and Its Emulsion on Biofilm-Associated Components ofAntibiotics (Basel, Switzerland) · 2025Article
- Motility of Acinetobacter baumannii: regulatory systems and controlling strategies.Applied microbiology and biotechnology · 2024Review
- Fluopsin C Promotes Biofilm Removal of XDRAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii (AB) is rising as a human pathogen of critical priority worldwide as it is the leading cause of chronic opportunistic infections in healthcare settings and the condition is ineradicable with antibiotic therapy. AB possesses the ability to form biofilm on abiotic as well as biotic surfaces which plays a major role in its pathogenesis and resistance in clinical settings. Hence, the demand for an alternative therapy to combat the biofilm-associated infections is increasing. The present study explored the antibiofilm potential of myrtenol, a bicyclic monoterpene present in various plants against reference and clinical strains of AB. Myrtenol (200 μg/mL) exhibited a strong antibiofilm activity without exerting any harmful effect on growth and metabolic viability of AB strains. Microscopic analyses confirmed the reduction in the biofilm thickness and surface coverage upon myrtenol treatment. Especially, myrtenol was found to be effective in disrupting the mature biofilms of tested AB strains. Furthermore, myrtenol inhibited the biofilm-associated virulence factors of AB strains such as extracellular polysaccharide, cell surface hydrophobicity, oxidant resistance, swarming and twitching motility. Transcriptional analysis unveiled the suppression of the biofilm-associated genes such as bfmR, csuA/B, bap, ompA, pgaA, pgaC, and katE by myrtenol. Notably, myrtenol improved the susceptibility of AB strains towards conventional antibiotics such as amikacin, ciprofloxacin, gentamicin and trimethoprim. Thus, the present study demonstrates the therapeutic potential of myrtenol against biofilm-associated infections of AB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.